NEW YORK — Aspira Women’s Health said on Thursday that it has acquired the exclusive rights to develop a microRNA-based ovarian cancer test based on technology developed at the Dana-Farber Cancer Institute.
Financial and other terms of the deal were not disclosed.
Aspira said that the test will use a blood-based miRNA signature developed at Dana-Farber in combination with the company’s proprietary algorithms — and potentially proteins and other factors — to assess ovarian cancer risk. It is expected to be included in Aspira’s OvaSuite portfolio of women’s health blood tests.
“Diagnosing ovarian cancer at its earliest stages is crucial to improving survival outcomes,” Aspira CSO and COO Ryan Phan said in a statement. “MicroRNA offers tremendous opportunity to make this a reality as it appears earlier compared with other testing targets, like circulating tumor cells or proteins.”
Aspira first began evaluating Dana-Farber’s miRNA technology in early 2021. The Austin, Texas-based company sponsors research by Dana-Farber and other institutions into the use of circulating miRNAs and proteins for the detection of endometriosis.
—————————————————-
Source link